GoodRx Holdings (GDRX) Cash & Current Investments (2019 - 2026)

GoodRx Holdings has disclosed Cash & Current Investments across 8 years of filings, most recently posting $235.7 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $235.7 million, down 21.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $235.7 million (down 21.69% YoY), and the FY2025 annual result was $261.8 million, down 41.6% from the prior year.
• Cash & Current Investments came in at $235.7 million for Q1 2026 at GoodRx Holdings, down from $261.8 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $845.4 million in Q1 2022 to a low of $235.7 million in Q1 2026.
• The 5-year median for Cash & Current Investments is $533.3 million (2024), against an average of $549.2 million.
• Across the five-year window, Cash & Current Investments climbed 9.07% in 2023 and tumbled 46.69% in 2024, its largest moves.
• GoodRx Holdings' Cash & Current Investments stood at $757.2 million in 2022, then retreated by 11.21% to $672.3 million in 2023, then plunged by 33.31% to $448.3 million in 2024, then tumbled by 41.6% to $261.8 million in 2025, then dropped by 9.97% to $235.7 million in 2026.
• The last three Cash & Current Investments figures came in at $235.7 million (Q1 2026), $261.8 million (Q4 2025), and $273.5 million (Q3 2025), per Business Quant data.